# CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

> **NCT05442515** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 126 (estimated)

## Conditions studied

- B-NHL
- B-Non Hodgkin Lymphoma
- Acute Lymphocytic Leukemia
- Acute Lymphoblastic Leukemia
- B-precursor ALL
- B-All
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, B Cell
- B-Cell Lymphoma
- B-Cell Leukemia
- Acute Lymphoid Leukemia

## Interventions

- **BIOLOGICAL:** CD19/CD22-CAR-transduced T cells
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine

## Key facts

- **NCT ID:** NCT05442515
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-28
- **Primary completion:** 2027-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442515, "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05442515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*